biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV is a biotech organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker AGMB. Primary therapeutic focus areas include Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
AGMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
AGMB-129
Phase 2 · small molecule · Fibrostenotic Crohn's Disease
AGMB-129 for Fibrostenotic Crohn's Disease is a Phase 2 program (small_molecule) at Agomab Therapeutics NV with 2 ClinicalTrials.gov record(s).
Internal code AGMB129-01-CL-109
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Agomab Therapeutics NV
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Fibrostenotic Crohn's Disease
- Status
- active
- Trials
- 2